The National Pharmaceutical Pricing Authority (NPPA) has revised the prices of 193 formulation packs based on 30 bulk drugs with effect from February 14, 2007. While few drugs of Eli Lilly, Ranbaxy, Novartis, Wyeth and Sandoz figured in the non-ceiling pricing, 162 formulations came under ceiling price fixation or revision.

The formulations are based on bulk drugs like analgin, multivitamin infusion (with amino acid), ibuprofen, vitamin E + C with combination, pseudoephedrine with combinations, pheniramine maleate, ranitidine with combinations, metronidazole with combinations, ibuprofen with combinations, vitamin A, griseofulvin, salbutamol with combinations, cloxacillin with combinations, chlorpromazine with combinations, dexamethasone with combintations, betamethasone valerate, metronidazole with combinations, dexamethasone with combintations, multivitamin, frusemide with combinations, trimethoprim with combinations, chinoform (ICHQ) with combinations, doxycycline hyclate with lactic acid bacillus, pyrantel pamoate with combinations, pseudoephedrine with combinations, naproxin sodium with combinations, betamethasone with combinations and prednisolone with combinations.

NPPA also withdrew the price regulation on betamethasone valerate + fusedic acid cream, through the notification, with immediate effect.

The non-ceiling pricing includes formulations from Aventis Pharma, Eli-Lilly and company (India) Pvt Ltd, Hindustan Antibiotics Ltd, Novartis, Ranbaxy Laboratories Limited, Sandoz Private Limited, Shreya Life Sciences and Wyeth Pharmaceuticals Ltd.